Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

Histofy and Indica Labs Collaborate to Integrate AI Solutions into Pathology Practice

NextEdge Admin

04 Jun 2024

3 min 0 sec

Histofy and Indica Labs have forged a collaboration aimed at integrating Histofy’s cutting-edge AI tools into clinical practice through the established HALO AP® platform. This partnership enables the seamless incorporation of Histofy’s advanced AI solutions into the daily workflows of pathologists.

HALO AP® stands as an AI-powered diagnostic pathology platform, facilitating primary diagnosis and routine workflows in anatomic pathology. It holds CE-IVDR mark in the EU, Switzerland, and the UK, demonstrating compliance with essential regulatory standards. Similarly, HALO AP Dx recently received FDA clearance for primary diagnosis in the United States.

Dr. Simon Graham, CTO at Histofy, expressed enthusiasm, highlighting the promise of integrating Histofy’s AI tools into HALO AP® to enhance diagnostic capabilities and efficiency for pathologists.

Eric Runde, Chief Operating Officer at Indica Labs, echoed this sentiment, emphasizing their dedication to providing pathologists with state-of-the-art tools for improved patient care.

This collaboration signifies a significant shift in pathology, leveraging AI to revolutionize diagnostic processes and enhance patient outcomes. As healthcare progresses, this partnership sets a precedent for future advancements in AI-driven pathology solutions.

HALO AP Dx holds FDA clearance for primary diagnostic use with the Hamamatsu NanoZoomer® S360MD Slide scanner in the US, ensuring compliance with FDA 21 CFR Part 11 and HIPAA. Meanwhile, HALO AP® is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland, and complies with FDA 21 CFR Part 11, HIPAA, and GDPR regulations.

Histofy specializes in transparent AI solutions for computational pathology, aiming to improve disease treatment, particularly cancer, through tissue-based diagnostics and prognostics.

Indica Labs is a leader in AI-powered digital pathology software, offering platforms like HALO and HALO AI for quantitative evaluation of whole slide images. Their HALO AP® and HALO AP Dx platforms provide enterprise digital pathology for primary diagnosis, with regulatory clearances in various markets.